Sanofi receives FDA approval for subcutaneous version of multiple myeloma drug Sarclisa
Sanofi (SNY) announced that its subcutaneously delivered formulation of Sarclisa, a treatment for multiple myeloma, has received FDA approval. The new version is branded as Sarclisa Escena and offers an alternative to the intravenous delivery currently available in the U.S.
Tickers: $SNY